2.0
28 Sept 2015
Former employee
Philadelphia, PA
Recommend
CEO approval
Business outlook
Pros
slow pace. Low cost of living compared to other pharma companies
Cons
constant reorganization. Management does not understand what can bring up productivity of R&D. British control and politics are every where.